Navigation Links
A new take on growth factor signaling in tamoxifen resistance
Date:6/23/2009

Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.

Sherene Loi, from the Peter MacCallum Cancer Centre, Melbourne, worked with a team of Australian and Belgian researchers to investigate the differences between those estrogen receptor positive (ER+) cancers that respond well to tamoxifen (luminal-A) and those that do not (luminal-B). She said, "This is the first study specifically investigating the biology of the luminal-B, ER+ breast cancer subtype. We propose that activation of GF signaling contributes to this highly proliferative, relatively tamoxifen-insensitive, phenotype and that this exists independently of HER2 overexpression. Targeting this pathway and its upstream mediators could prove to be a useful therapeutic strategy".

The researchers used a new computational method of analysis of gene expression data called gene set enrichment analysis (GSEA) to determine that there is increased growth factor activation from the gene expression profiles of nearly 100 luminal-B breast cancers samples. They then validated this finding by showing that treatment with the growth factor heregulin, which induced growth factor signaling an in-vitro model, could overcome tamoxifen-induced cell cycle arrest.

This research represents a departure from the informative, but sometimes not terribly useful, process of identifying genes associated with given conditions. Dr Loi said, "Although gene expression data has demonstrated its ability to identify subsets of disease and predict outcomes or drug responses, identifying new therapeutic approaches based on whole genome microarray profiling has, to date, been a significant challenge. By using GSEA, we've been able to use gene expression data to identify that activation of GF signaling pathways as a possible therapeutic target for further exploration in the clinical setting for these particular breast cancer patients".


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-203-192-2165
BioMed Central
Source:Eurekalert

Related medicine news :

1. High pollution linked to poor lung function growth in children in Mexico City
2. Researchers develop long-lasting growth hormone
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
5. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
6. AWT Management Announce Aggressive Growth and Acquisition Strategy
7. Cynosure to Present at the Maxim Group Growth Conference
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
10. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Patients who ... Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with or ... simultaneously improving their oral health and functionality. , Dr. Bedich offers a ...
(Date:5/24/2017)... Lehi, Utah (PRWEB) , ... May 24, 2017 , ... ... “Super Sick Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal ... 31, 2017, at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a ... CIO Applications magazine has named the company a “Top 25 Cybersecurity Companies 2017.” ... Cloud to help organizations simply and proactively address potential cybersecurity threats before they happen. ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
Breaking Medicine Technology: